Drugs & Targets FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression May 16, 2025Vol.51 No.19
Drugs & Targets FDA approves Zynyz as first-line treatment for advanced anal cancer May 16, 2025Vol.51 No.19
Regulatory News Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies May 09, 2025Vol.51 No.18By Claire Marie Porter
Cancer Policy Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Cancer Policy First ODAC meeting since Trump’s inauguration scheduled for May 20-21 May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC May 09, 2025Vol.51 No.18
Clinical Roundup Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment May 02, 2025Vol.51 No.17
Regulatory News Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industryCommissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas April 25, 2025Vol.51 No.16By Claire Marie Porter
Cancer Policy ASCO seeks to engage new leaders of NIH, CMS, and FDA April 25, 2025Vol.51 No.16By Jacquelyn Cobb
In Brief FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine April 25, 2025Vol.51 No.16
